1887

Abstract

Candidate human immunodeficiency virus type 1 (HIV-1) vaccines focusing on T-cell induction, constructed as pTHr.HIVA DNA and modified vaccinia virus Ankara (MVA).HIVA, were delivered in a heterologous prime–boost regimen. The vaccines were tested in several hundred healthy or HIV-1-infected volunteers in Europe and Africa. Whilst larger trials of hundreds of volunteers suggested induction of HIV-1-specific T-cell responses in <15 % of healthy vaccinees, a series of small, rapid trials in 12–24 volunteers at a time with a more in-depth analysis of vaccine-elicited T-cell responses proved to be highly informative and provided more encouraging results. These trials demonstrated that the pTHr.HIVA vaccine alone primed consistently weak and mainly CD4, but also CD8 T-cell responses, and the MVA.HIVA vaccine delivered a consistent boost to both CD4 and CD8 T cells, which was particularly strong in HIV-1-infected patients. Thus, whilst the search is on for ways to enhance T-cell priming, MVA is a useful boosting vector for human subunit genetic vaccines.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82493-0
2007-01-01
2021-01-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/1/1.html?itemId=/content/journal/jgv/10.1099/vir.0.82493-0&mimeType=html&fmt=ahah

References

  1. AIDS Vaccine Evaluation Group 022 Protocol Team; 2001; Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis 183:563–570 [CrossRef]
    [Google Scholar]
  2. Allen T. M., Vogel T. U., Fuller D. H., Mothe B. R., Steffen S., Boyson J. E., Shipley T., Fuller J., Hanke T. other authors 2000; Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 164:4968–4978 [CrossRef]
    [Google Scholar]
  3. Allen T. M., Jing P., Calore B., Horton H., O'Connor D. H., Hanke T., Piekarczyk M., Ruddersdorf R., Mothe B. R. other authors 2002; Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol 76:10507–10511 [CrossRef]
    [Google Scholar]
  4. Amara R. R., Villinger F., Altman J. D., Lydy S. L., O'Neil S. P., Staprans S. I., Montefiori D. C., Xu Y., Herndon J. G. other authors 2001; Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69–74 [CrossRef]
    [Google Scholar]
  5. Anonymous. 2002; Use of AAV vectors in AIDS vaccine. Expert Rev Vaccines 1:7
    [Google Scholar]
  6. Anonymous. 2004; NIAID begins enrolling volunteers for Phase IIB study of Merck's vaccine. IAVI Rep 9:16
    [Google Scholar]
  7. Anonymous. 2005; Clinical trials yield promising results from two adenovirus-based vaccines. IAVI Rep 9:24
    [Google Scholar]
  8. Appay V., Dunbar P. R., Callan M., Klenerman P., Gillespie G. M., Papagno L., Ogg G. S., King A., Lechner F. other authors 2002; Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8:379–385 [CrossRef]
    [Google Scholar]
  9. Barber D. L., Wherry E. J., Masopust D., Zhu B., Allison J. P., Sharpe A. H., Freeman G. J., Ahmed R. 2006; Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682–687 [CrossRef]
    [Google Scholar]
  10. Barouch D. H., Nabel G. J. 2005; Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16:149–156 [CrossRef]
    [Google Scholar]
  11. Barouch D. H., Santra S., Schmitz J. E., Kuroda M. J., Fu T. M., Wagner W., Bilska M., Craiu A., Zheng X. X. other authors 2000; Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486–492 [CrossRef]
    [Google Scholar]
  12. Barouch D. H., Santra S., Tenner-Racz K., Racz P., Kuroda M. J., Schmitz J. E., Jackson S. S., Lifton M. A., Freed D. C. other authors 2002; Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 168:562–568 [CrossRef]
    [Google Scholar]
  13. Belshe R. B., Gorse G. J., Mulligan M. J., Evans T. G., Keefer M. C., Excler J. L., Duliege A. M., Tartaglia J., Cox W. I. other authors 1998; Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 12:2407–2415 [CrossRef]
    [Google Scholar]
  14. Bins A. D., Jorritsma A., Wolkers M. C., Hung C. F., Wu T. C., Schumacher T. N., Haanen J. B. 2005; A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 11:899–904 [CrossRef]
    [Google Scholar]
  15. Cao H., Kaleebu P., Hom D., Flores J., Agrawal D., Jones N., Serwanga J., Okello M., Walker C. other authors 2003; Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infect Dis 187:887–895 [CrossRef]
    [Google Scholar]
  16. Casimiro D. R., Bett A. J., Fu T. M., Davies M. E., Tang A., Wilson K. A., Chen M., Long R., McKelvey T. other authors 2004; Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78:11434–11438 [CrossRef]
    [Google Scholar]
  17. Cebere I., Dorrell L., McShane H., Simmons A., McCormack S., Schmidt C., Smith C., Brooks M., Roberts J. E. other authors 2006; Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24:417–425 [CrossRef]
    [Google Scholar]
  18. Chakrabarti S., Brechling K., Moss B. 1985; Vaccinia virus expression vector: coexpression of β -galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 5:3403–3409
    [Google Scholar]
  19. Choi M. J., Maibach H. I. 2003; Topical vaccination of DNA antigens: topical delivery of DNA antigens. Skin Pharmacol Appl Skin Physiol 16:271–282 [CrossRef]
    [Google Scholar]
  20. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D. H., Sutter G., Goebel F. D., Erfle V. 2003; Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22:21–29 [CrossRef]
    [Google Scholar]
  21. Czerkinsky C. C., Tarkowski A., Nilsson L. A., Ouchterlony O., Nygren H., Gretzer C. 1984; Reverse enzyme-linked immunospot assay (RELISPOT) for the detection of cells secreting immunoreactive substances. J Immunol Methods 72:489–496 [CrossRef]
    [Google Scholar]
  22. Davenport M. P., Ribeiro R. M., Chao D. L., Perelson A. S. 2004; Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol 78:11340–11351 [CrossRef]
    [Google Scholar]
  23. Davis N. L., West A., Reap E., Macdonald G., Collier M., Dryga S., Maughan M., Connell M., Walker C. other authors 2002; Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 53:209–211 [CrossRef]
    [Google Scholar]
  24. Dorrell L., Yang H., Iversen A. K., Conlon C., Suttill A., Lancaster M., Dong T., Cebere I., Edwards A. other authors 2005; Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS 19:1321–1323 [CrossRef]
    [Google Scholar]
  25. Dorrell L., Yang H., Ondondo B., Dong T., di Gleria K., Suttill A., Conlon C., Brown D., Williams P. other authors 2006; Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 80:4705–4716 [CrossRef]
    [Google Scholar]
  26. Douek D. C., Kwong P. D., Nabel G. J. 2006; The rational design of an AIDS vaccine. Cell 124:677–681 [CrossRef]
    [Google Scholar]
  27. Estcourt M. J., Ramsay A. J., Brooks A., Thomson S. A., Medveckzy C. J., Ramshaw I. A. 2002; Prime–boost immunization generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population. Int Immunol 14:31–37 [CrossRef]
    [Google Scholar]
  28. Estcourt M. J., McMichael A. J., Hanke T. 2004; DNA vaccines against human immunodeficiency virus type 1. Immunol Rev 199:144–155 [CrossRef]
    [Google Scholar]
  29. Estcourt M. J., McMichael A. J., Hanke T. 2005a; Altered primary CD8+ T cell response to a modified virus Ankara (MVA)-vectored vaccine in the absence of CD4+ T cell help. Eur J Immunol 35:3460–3467 [CrossRef]
    [Google Scholar]
  30. Estcourt M. J., Letourneau S., McMichael A. J., Hanke T. 2005b; Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. Eur J Immunol 35:2532–2540 [CrossRef]
    [Google Scholar]
  31. Evans T. G., Keefer M. C., Weinhold K. J., Wolff M., Montefiori D., Gorse G. J., Graham B. S., McElrath M. J., Clements-Mann M.-L. other authors 1999; A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 180:290–298 [CrossRef]
    [Google Scholar]
  32. Farina S. F., Gao G. P., Xiang Z. Q., Rux J. J., Burnett R. M., Alvira M. R., Marsh J., Ertl H. C., Wilson J. M. 2001; Replication-defective vector based on a chimpanzee adenovirus. J Virol 75:11603–11613 [CrossRef]
    [Google Scholar]
  33. Ferrantelli F., Ruprecht R. M. 2002; Neutralizing antibodies against HIV – back in the major leagues?. Curr Opin Immunol 14:495–502 [CrossRef]
    [Google Scholar]
  34. Ferrari G., Humphrey W., McElrath M. J., Excler J. L., Duliege A. M., Clements M. L., Corey L. C., Bolognesi D. P., Weinhold K. J. 1997; Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 94:1396–1401 [CrossRef]
    [Google Scholar]
  35. Franchini G., Gurunathan S., Baglyos L., Plotkin S., Tartaglia J. 2004; Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 3:S75–S88 [CrossRef]
    [Google Scholar]
  36. Gilbert S. C., Schneider J., Plebanski M., Hannan C. M., Blanchard T. J., Smith G. L., Hill A. V. S. 1999; Ty virus-like particles, DNA vaccines and modified vaccinia virus Ankara; comparison and combinations. Biol Chem 380:299–303
    [Google Scholar]
  37. Gilbert S. C., Schneider J., Hannan C. M., Hu J. T., Plebanski M., Sinden R., Hill A. V. 2002; Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20:1039–1045 [CrossRef]
    [Google Scholar]
  38. Global HIV/AIDS Vaccine Enterprise 2005; The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med 2:e25 [CrossRef]
    [Google Scholar]
  39. Goonetilleke N., Moore S., Dally L., Winstone N., Mahmoud N., Cebere I., Pinheiro S., Gillespie G., Brown D. other authors 2006; Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 80:4717–4728 [CrossRef]
    [Google Scholar]
  40. Gupta K., Hudgens M., Corey L., McElrath M. J., Weinhold K., Montefiori D. C., Gorse G. J., Frey S. E., Keefer M. C. other authors 2002; Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 29:254–261 [CrossRef]
    [Google Scholar]
  41. Gursel M., Verthelyi D., Gursel I., Ishii K. J., Klinman D. M. 2002; Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol 71:813–820
    [Google Scholar]
  42. Hanke T., McMichael A. J. 2000; Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6:951–955 [CrossRef]
    [Google Scholar]
  43. Hanke T., Schneider J., Gilbert S. C., Hill A. V. S., McMichael A. 1998a; DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum : immunogenicity in mice. Vaccine 16:426–435 [CrossRef]
    [Google Scholar]
  44. Hanke T., Blanchard T. J., Schneider J., Hannan C. M., Becker M., Gilbert S. C., Hill A. V. S., Smith G. L., McMichael A. 1998b; Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16:439–445 [CrossRef]
    [Google Scholar]
  45. Hanke T., Samuel R. V., Blanchard T. J., Neumann V. C., Allen T. M., Boyson J. E., Sharpe A. S., Cook N., Smith G. L. other authors 1999; Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 73:7524–7532
    [Google Scholar]
  46. Hanke T., McMichael A. J., Samuel R. V., Powell L. A. J., McLoughlin L., Crome S. J., Edlin A. 2002; Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 21:108–114 [CrossRef]
    [Google Scholar]
  47. Hanke T., Barnfield C., Wee E. G.-T., Ågren L., Samuel R. V., Larke N., Liljeström P. 2003; Construction and immunogenicity in a prime–boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 84:361–368 [CrossRef]
    [Google Scholar]
  48. Hanke T., McMichael A. J., Dennis M. J., Sharpe S. A., Powell L. A. J., McLoughlin L., Crome S. J. 2005; Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 23:1507–1514 [CrossRef]
    [Google Scholar]
  49. Harari A., Zimmerli S. C., Pantaleo G. 2004a; Cytomegalovirus (CMV)-specific cellular immune responses. Hum Immunol 65:500–506 [CrossRef]
    [Google Scholar]
  50. Harari A., Vallelian F., Pantaleo G. 2004b; Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur J Immunol 34:3525–3533 [CrossRef]
    [Google Scholar]
  51. Harrer E., Bauerle M., Ferstl B., Chaplin P., Petzold B., Mateo L., Handley A., Tzatzaris M., Vollmar J. other authors 2005; Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 10:285–300
    [Google Scholar]
  52. Haynes J. R., Fuller D. H., McCabe D., Swain W. F., Widera G. 1996; Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization. Adv Drug Delivery Rev 21:3–18 [CrossRef]
    [Google Scholar]
  53. Hutchings C. L., Gilbert S. C., Hill A. V., Moore A. C. 2005; Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 175:599–606 [CrossRef]
    [Google Scholar]
  54. Im E.-J., Hanke T. 2004; MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 3:S89–S97 [CrossRef]
    [Google Scholar]
  55. Im E.-J., Nkolola J. P., di Gleria K., McMichael A. J., Hanke T. 2006; Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. Eur J Immunol 36:2574–2584 [CrossRef]
    [Google Scholar]
  56. Jin X., Ramanathan M. Jr, Barsoum S., Deschenes G. R., Ba L., Binley J., Schiller D., Bauer D. E., Chen D. C. other authors 2002; Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 76:2206–2216 [CrossRef]
    [Google Scholar]
  57. Korber B., Foley B., Leitner T., McCutchan F., Hahn B., Mellors J. W., Myers G. Kuiken C. (editors) 1997 Human retroviruses and AIDS 1997: a complilation and analysis of nucleic acid and amino acid sequences Los Alamos, NM: Los Alamos National Laboratory;
    [Google Scholar]
  58. Koshkina N. V., Agoulnik I. Y., Melton S. L., Densmore C. L., Knight V. 2003; Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. Mol Ther 8:249–254 [CrossRef]
    [Google Scholar]
  59. Lalvani A., Brookes R., Hambleton S., Britton W. J., Hill A. V. S., McMichael A. J. 1997; Rapid effector function in CD8+ memory T cells. J Exp Med 186:859–865 [CrossRef]
    [Google Scholar]
  60. Larke N., Murphy A., Wirblich C., Teoh D., Estcourt M. J., McMichael A. J., Roy P., Hanke T. 2005; Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen. J Virol 79:14822–14833 [CrossRef]
    [Google Scholar]
  61. Leifer C. A., Verthelyi D., Klinman D. M. 2003; Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J Immunother 26:313–319 [CrossRef]
    [Google Scholar]
  62. Levy Y., Gahery-Segard H., Durier C., Lascaux A. S., Goujard C., Meiffredy V., Rouzioux C., El Habib R., Beumont-Mauviel M. other authors 2005; Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 19:279–286
    [Google Scholar]
  63. Levy Y., Durier C., Lascaux A. S., Meiffredy V., Gahery-Segard H., Goujard C., Rouzioux C., Resch M., Guillet J. G. other authors 2006; Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 20:405–413 [CrossRef]
    [Google Scholar]
  64. Maino V. C., Picker L. J. 1998; Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry 34:207–215 [CrossRef]
    [Google Scholar]
  65. McShane H., Pathan A. A., Sander C. R., Keating S. M., Gilbert S. C., Huygen K., Fletcher H. A., Hill A. V. 2004; Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10:1240–1244 [CrossRef]
    [Google Scholar]
  66. Moorthy V. S., Pinder M., Reece W. H., Watkins K., Atabani S., Hannan C., Bojang K., McAdam K. P., Schneider J. other authors 2003; Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J Infect Dis 188:1239–1244 [CrossRef]
    [Google Scholar]
  67. Mosteller R. D. 1987; Simplified calculation of body-surface area. N Engl J Med 317:1098
    [Google Scholar]
  68. Musey L., Ding Y., Elizaga M., Ha R., Celum C., McElrath M. J. 2003; HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals. J Immunol 171:1094–1101 [CrossRef]
    [Google Scholar]
  69. Mwau M., McMichael A. J., Hanke T. 2002; Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses 18:611–618 [CrossRef]
    [Google Scholar]
  70. Mwau M., Cebere I., Sutton J., Chikoti P., Winstone N., Wee E. G.-T., Beattie T., Chen Y.-H., Dorrel L. other authors 2004; A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85:911–919 [CrossRef]
    [Google Scholar]
  71. Nkolola J. P., Wee E. G.-T., Im E.-J., Jewell C. P., Chen N., Xu X.-N., McMichael A. J., Hanke T. 2004; Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther 11:1068–1080 [CrossRef]
    [Google Scholar]
  72. Nordström E. K. L., Forsell M. N. E., Barnfield C., Bonin E., Hanke T., Sundström M., Karlsson G. B., Liljeström P. 2005; Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J Gen Virol 86:349–354 [CrossRef]
    [Google Scholar]
  73. Ondondo B. O., Yang H., Dong T., di Gleria K., Suttill A., Conlon C., Brown D., Williams P., Rowland-Jones S. L. other authors 2006; Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Eur J Immunol 36:2585–2594 [CrossRef]
    [Google Scholar]
  74. Raviprakash K., Ewing D., Simmons M., Porter K. R., Jones T. R., Hayes C. G., Stout R., Murphy G. S. 2003; Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315:345–352 [CrossRef]
    [Google Scholar]
  75. Robbins G. K., Addo M. M., Troung H., Rathod A., Habeeb K., Davis B., Heller H., Basgoz N., Walker B. D., Rosenberg E. S. 2003; Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS 17:1121–1126 [CrossRef]
    [Google Scholar]
  76. Roberts D. M., Nanda A., Havenga M. J., Abbink P., Lynch D. M., Ewald B. A., Liu J., Thorner A. R., Swanson P. E. other authors 2006; Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:239–243 [CrossRef]
    [Google Scholar]
  77. Rosenberg E. S., Billingsley J. M., Caliendo A. M., Boswell S. L., Sax P. E., Kalams S. A., Walker B. D. 1997; Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447–1450 [CrossRef]
    [Google Scholar]
  78. Rowland-Jones S. L., Pinheiro S., Kaul R., Hansasuta P., Gillespie G., Dong T., Plummer F. A., Bwayo J. B., Fidler S. other authors 2001; How important is the ‘quality’ of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection?. Immunol Lett 79:15–20 [CrossRef]
    [Google Scholar]
  79. Santra S., Barouch D. H., Korioth-Schmitz B., Lord C. I., Krivulka G. R., Yu F., Beddall M. H., Gorgone D. A., Lifton M. A. other authors 2004; Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci U S A 101:11088–11093 [CrossRef]
    [Google Scholar]
  80. Schneider J., Gilbert S. C., Blanchard T. J., Hanke T., Robson K. J., Hannan C. M., Becker M., Sinden R., Smith G. L., Hill A. V. S. 1998; Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4:397–402 [CrossRef]
    [Google Scholar]
  81. Schulz O., Diebold S. S., Chen M., Naslund T. I., Nolte M. A., Alexopoulou L., Azuma Y. T., Flavell R. A., Liljeström P. other authors 2005; Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433:887–892 [CrossRef]
    [Google Scholar]
  82. Slyker J. A., Lohman B. L., Mbori-Ngacha D. A., Reilly M., Wee E. G., Dong T., McMichael A. J., Rowland-Jones S. L., Hanke T., John-Stewart G. 2005; Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants. Vaccine 23:4711–4719 [CrossRef]
    [Google Scholar]
  83. Sun J. C., Williams M. A., Bevan M. J. 2004; CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5:927–933 [CrossRef]
    [Google Scholar]
  84. Tubiana R., Carcelain G., Vray M., Gourlain K., Dalban C., Chermak A., Rabian C., Vittecoq D., Simon A. other authors 2005; Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 23:4292–4301 [CrossRef]
    [Google Scholar]
  85. UNAIDS 2004 AIDS Epidemic Update: December 2004 Geneva: UNAIDS/WHO; http://www.who.int/hiv/pub/epidemiology/epiupdate/en/index.html
    [Google Scholar]
  86. van Baalen C. A., Guillon C., van Baalen M., Verschuren E. J., Boers P. H., Osterhaus A. D., Gruters R. A. 2002; Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes. Eur J Immunol 32:2644–2652 [CrossRef]
    [Google Scholar]
  87. Vordermeier H. M., Rhodes S. G., Dean G., Goonetilleke N., Huygen K., Hill A. V., Hewinson R. G., Gilbert S. C. 2004; Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 112:461–470 [CrossRef]
    [Google Scholar]
  88. Vuola J. M., Keating S., Webster D. P., Berthoud T., Dunachie S., Gilbert S. C., Hill A. V. 2005; Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 174:449–455 [CrossRef]
    [Google Scholar]
  89. Webster D. P., Dunachie S., Vuola J. M., Berthoud T., Keating S., Laidlaw S. M., McConkey S. J., Poulton I., Andrews L. other authors 2005; Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 102:4836–4841 [CrossRef]
    [Google Scholar]
  90. Wee E. G.-T., Patel S., McMichael A. J., Hanke T. 2002; A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J Gen Virol 83:75–80
    [Google Scholar]
  91. Williams S. G., Cranenburgh R. M., Weiss A. M. E., Wrighton C. J., Sherratt D. J., Hanak J. A. J. 1998; Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 26:2120–2124 [CrossRef]
    [Google Scholar]
  92. Williams A., Goonetilleke N. P., McShane H., Clark S. O., Hatch G., Gilbert S. C., Hill A. V. 2005; Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun 73:3814–3816 [CrossRef]
    [Google Scholar]
  93. Zhang D., Shankar P., Xu Z., Harnisch B., Chen G., Lange C., Lee S. J., Valdez H., Lederman M. M., Lieberman J. 2003a; Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 101:226–235 [CrossRef]
    [Google Scholar]
  94. Zhang L., Widera G., Bleecher S., Zaharoff D. A., Mossop B., Rabussay D. 2003b; Accelerated immune response to DNA vaccines. DNA Cell Biol 22:815–822 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82493-0
Loading
/content/journal/jgv/10.1099/vir.0.82493-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error